Opposing roles for Egalitarian and Staufen in transport, anchoring and localization of oskar mRNA in the Drosophila oocyte

Summary

Localization of oskar mRNA includes two distinct phases: transport from nurse cells to the oocyte, a process typically accompanied by cortical anchoring in the oocyte, followed by posterior localization within the oocyte. Signals within the oskar 3’ UTR directing transport are individually weak, a feature previously hypothesized to facilitate exchange between the different localization machineries. We show that alteration of the SL2a stem-loop structure containing the oskar transport and anchoring signal (TAS) removes an inhibitory effect such that in vitro binding by the RNA transport factor, Egalitarian, is elevated as is in vivo transport from the nurse cells into the oocyte. Cortical anchoring within the oocyte is also enhanced, interfering with posterior localization. We also show that mutation of Staufen recognized structures (SRSs), predicted binding sites for Staufen, disrupts posterior localization of oskar mRNA just as in staufen mutants. Two SRSs in SL2a, one overlapping the Egalitarian binding site, are inferred to mediate Staufen-dependent inhibition of TAS anchoring activity, thereby promoting posterior localization. The other three SRSs in the oskar 3’ UTR are also required for posterior localization, including two located distant from any known transport signal. Staufen, thus, plays multiple roles in localization of oskar mRNA.

Keywords:

3' UTR – Eggs – Embryos – Luciferase – Oocytes – Oogenesis – RNA transport – Transport inhibition assay

Introduction

Localization of mRNAs serves to target expression of encoded proteins to specific subcellular domains [1,2]. One extensively studied example is the oskar (osk) mRNA: through localization, the mRNA becomes positioned at the posterior pole of the developing Drosophila oocyte, the site where the OSK protein acts to recruit factors that establish the embryonic germ line and pattern the posterior region of the embryo [3]. Appearance of OSK protein outside this domain leads to the lethal reorganization of the embryo, with duplicated ectopic posterior pattern elements replacing anterior structures to form bicaudal embryos [4,5].

Cellular RNAs have two general roles. They can encode proteins, or they can function as noncoding RNAs (ncRNAs). Unusually, osk mRNA does both, with a noncoding role required for progression through oogenesis [6]. At the earlier stages of oogenesis when osk ncRNA activity is required, the mRNA is efficiently transported from nurse cells (the sites of transcription) through ring canals into the oocyte; if this transport is disrupted, osk ncRNA activity is also disrupted [7]. Thus, both the coding and noncoding roles of osk mRNA require some form of localization. Here, we refer to the two phases of osk mRNA localization as ‘transport’ (directed movement from nurse cells to oocyte) and ‘localization’ (directed movement within the oocyte to the posterior at later stages of oogenesis).

Transport of osk mRNA into the oocyte is mediated by multiple regulatory elements in its 3’ UTR. Those embedded within two stem-loop (SL) structures, SL2a and SL2b, are most critical and deletion of either SL greatly reduces transport [8–11]. The SL2a signal has been mapped at high resolution and corresponds to the most highly conserved portion of the stem structure [11]. Neither SL2a nor SL2b has strong transport activity on its own; if either is added to a reporter mRNA, there is very limited transport to the oocyte [7,10,11]. By contrast, another stem-loop signal—the TLS—that mediates transport of the fs(1)K10 mRNA from nurse cells to the oocyte is highly active in isolation: addition of the 44 nucleotide TLS to foreign mRNAs consistently confers highly efficient transport [12].

Because transport of osk mRNA is essential, it might seem odd that the individual osk signals are weak, even if they are collectively strong. A possible explanation of this paradox was suggested by features of the TLS-type transport mechanism and the peculiar properties of osk mRNA localization. Importantly, the TLS mediates not only transport to the oocyte but also anchoring [12]. Starting in stage 8 of oogenesis, the mRNA becomes anchored at the anterior, cortical regions of the oocyte after transport. Because the mRNA enters the oocyte at its anterior end, anchoring may be ‘cortical-specific’ rather than ‘anterior-specific’, with the anterior distribution being a consequence of where the newly transported mRNA first encounters the anchoring substrate. If the TLS-type mechanism, which acts on multiple mRNAs and in a variety of cell types [10,13], also mediates transport of osk mRNA into the oocyte, then osk mRNA should also be restrained at or near the anterior by cortical anchoring. But this is a problem, because osk mRNA needs to be displaced from the anterior in the course of its localization to the posterior of the oocyte. We have proposed that individual osk transport signals are weak by necessity to facilitate release from the transport and anchoring machinery, thereby allowing the posterior localization machinery to efficiently move the mRNA to its final destination [11]. Support for this model came from adding the strong TLS to the osk mRNA, either as a simple addition or as a substitution for SL2a or SL2b: the result is inappropriate anchoring in anterior and lateral cortical regions of the oocyte, together with reduced efficiency of posterior localization of the mRNA.

A prediction of the ‘weak by necessity’ model is that osk mRNA transport relies on the same components that act on the TLS, thus conferring not only transport but also anchoring. The TLS is recognized and bound by Egalitarian (EGL), acting in concert with BicaudalD (BICD) [14]. Transport of the complex is driven by Dynein along microtubules [14]. EGL has been shown to be associated with osk mRNA, although it remains unknown whether this binding is direct [15]. If EGL binds directly to the osk transport signals, this binding may be constrained in some way to account for the weak activity of the individual signals. This constraint might be achieved by, for example, inherently low affinity of the osk transport signals for EGL or competition between EGL and inhibitory factors.

Here we report that a specific alteration of SL2a removes an inhibitory influence, dramatically strengthening both transport and cortical anchoring. In the context of osk mRNA, the uninhibited transport and anchoring signal (TAS) behaves like the TLS, disrupting posterior localization of the mRNA within the oocyte. In the context of a reporter mRNA (i.e., lacking sequences that direct posterior localization), the uninhibited TAS directs both transport and cortical anchoring. Release from inhibition in the altered SL2a correlates with enhanced EGL binding in vitro. The double-stranded RNA binding protein Staufen (STAU) has been implicated in posterior localization of osk mRNA [16–18]. The osk mRNA has been shown to be bound by STAU and several ‘STAU recognized structures’ (SRSs) have been predicted in the osk 3’ UTR [19]. We show here that mutation of SRSs in osk reduces association with STAU. Two SRSs lie within SL2a, with one overlapping the EGL binding site, suggesting that STAU may compete with EGL for binding. Consistent with this model, loss of STAU activity enhances transport and cortical anchoring of reporter mRNAs with SL2a. Additional SRSs elsewhere in the osk mRNA 3’ UTR are also required for posterior localization, likely acting by a different mechanism.

Results

A mutant form of the SL2a transport signal possesses enhanced transport and anchoring activity

In prior work to define the sequence and structure of the SL2a transport signal, we characterized genomic osk transgenes with mutant forms of SL2a. Only mutants with alterations within the central, most highly conserved portion of SL2a are defective for transport [11]. Although changes in other portions of SL2a do not substantially impede transport, one mutant, osk 3’Δ550–597 tl (Fig 1A), was unusual: as oogenesis progressed, the mutant mRNA was inappropriately retained at or near the anterior of the oocyte (Fig 1B). As in some situations when osk mRNA is mislocalized to the anterior of the oocyte [4], this ectopic osk distribution resulted in formation of bicaudal embryos (Fig 1C).

Because the osk 3’Δ550–597 tl mRNA distribution was similar to that of osk mRNAs to which the strong TLS transport and anchoring signal had been added (Fig 1B) [11], it seemed likely that the abbreviated form of SL2a in osk 3’Δ550–597 tl possessed enhanced activity, at least for anchoring. If so, introducing a mutation that reduces SL2a activity might be expected to eliminate mRNA mislocalization caused by enhanced anchoring. Mutations in the SL2a transport signal that strongly reduce transport are not suitable for this approach: disruption of osk RNA transport to the oocyte inhibits osk ncRNA activity and thus causes arrest of oogenesis [7,11], resulting in few to none of the later stage egg chambers in which mislocalization can be assessed. Furthermore, the rare eggs laid fail to develop, eliminating the option of scoring for embryonic patterning defects. However, a more subtle substitution mutation within the SL2a signal (osk 3’ 539–540; Fig 1A and 1C) was useful. When incorporated into osk 3’Δ550–597 tl, the enhanced anchoring phenotypes were dramatically suppressed. At the RNA level, no mislocalized osk 3’Δ550–597 tl 539–540 mRNA could be detected above background (Fig 1B). In a more sensitive biological read out—embryonic patterning—only a small fraction of embryos from osk 3’Δ550–597 tl 539–540 mothers showed evidence of ectopic osk activity in the form of weak anterior defects, and no embryos were bicaudal (Fig 1C). Thus, the behavior of the osk 3’Δ550–597 tl mutant does appear to be due to enhanced activity of the SL2a transport and anchoring signal, referred to henceforth as the TAS.

By analogy to the TLS, the enhanced anchoring activity of the osk 3’Δ550–597 tl mutant might be expected to be accompanied by increased transport activity. Because of the normally strong transport of osk mRNA to the oocyte, a further increase in transport activity would be difficult to detect; therefore, we used a GFP reporter mRNA assay. Addition of wild-type SL2a to a reporter is known to confer very little transport activity, allowing detection of increased transport by SL2a mutants (for comparison, the complete SL2 confers strong transport; Fig 1D–1F) [7,10,11]. As expected, the Δ550–597 tl version of SL2a directed robust transport (Fig 1D–1F). In stage 8–9 oocytes the mRNA was enriched in the cortical regions, highest near the anterior, and diminishing towards the posterior (Fig 1E’); thus, it is strongly anchored. We conclude that the TAS behaves much like the TLS and that its anchoring activity is inhibited in the context of the complete SL2a.

Before addressing which changes in the osk 3’ Δ550–597 tl mutant can relieve inhibition of TAS transport and cortical anchoring activity (below), we first describe additional experiments to ask if other changes in SL2a also affect TAS activity in the GFP reporter assay. In particular, because the TAS lies in the central part of the SL2a stem-loop, we asked if removing the proximal part (in Δproximal; Fig 1D) had the same relief from inhibition as removal of the distal part; however, there was only a slight increase in transport to the oocyte (Fig 1E and 1F). The fraction of Δproximal mutant reporter mRNA in the oocyte, which could only be visualized by enhancing the sensitivity of detection, showed no evidence of cortical anchoring (Fig 1E’). We also tested the isolated TAS (TAS tl), as well as a version with a synthetic extension to the base of the stem, to stabilize folding into a stem-loop (TAS tl+clamp). Both had transport and anchoring activity (Fig 1E and 1F).

Which changes in the osk 3’Δ550–597 tl mutant relieve TAS inhibition?

Based on the predicted structure of SL2a (supported by mutational analysis [11]), two general effects, which are not mutually exclusive, may have caused relief of TAS inhibition in the osk 3’Δ550–597 tl mutant. First, the mutant could be missing a binding site for an inhibitory factor that normally interferes with binding of a transport/anchoring factor such as EGL. The inhibitory factor could, for example, alter TAS folding or bind close to the TAS to inhibit binding by EGL. In the second, the osk 3’Δ550–597 tl mutant could have enhanced affinity for a transport/anchoring factor independent of any inhibitory factor.

To explore these possibilities several additional mutants were tested (Fig 2). The first retained all features of 3’Δ550–597 tl except for the tetraloop (osk 3’Δ550–597 bl; Fig 2A). Tetraloops stabilize or enhance folding of adjacent stem regions [20,21] and one was included in the osk 3’Δ550–597 tl mutant to compensate for a predicted reduction in folding stability due to the loss of the extended terminal stem region. Although the mutant without the tetraloop had hyperactivity phenotypes less extreme than for osk 3’Δ550–597 tl, anterior mislocalization of the mutant mRNAs was readily detected (Fig 2B) and all embryos were bicaudal (Fig 2C). Thus, osk 3’Δ550–597 bl substantially relieves inhibition of TAS activity independent of the presence of the tetraloop.

We next asked if bases flanking the TAS in SL2a and predicted to be unpaired (see Fig 2A) act to limit TAS activity. Some (osk 3’Δunp) or all (osk 3’Δunpall) of these were deleted with no other changes in SL2a (Fig 2A). Neither mutant mRNA was detectably mislocalized at the anterior (Fig 2B) but, in the sensitive embryonic body patterning assay, anterior defects were present in 1.0% (osk 3’Δunp) or 3.3% (osk 3’Δunpall) of the embryos, indicating a very low level of ectopic osk activity (Fig 2C).

Finally, we tested mutants that were similar to osk 3’Δ550–597 tl but removed less of the distal SL2a stem. Both osk 3’Δ559–588 tl and osk 3’Δ563–583 tl (Fig 2A) mRNAs were mislocalized at the anterior at low but significant levels (Fig 2B). Consistent with these results, in the body patterning assay anterior defects were present in 2.9% (osk 3’Δ559–588 tl) or 4.6% (osk 3’Δ563–583 tl) of the embryos (Fig 2C). Thus, the presence of a stable stem contributes to inhibition of TAS activity.

In conclusion, these results show that relief of TAS inhibition in osk 3’Δ550–597 tl cannot be wholly ascribed to a single type of change in SL2a. Instead, each recognizable type makes a contribution, and both of the two general options to explain the normally low activity of SL2a –inherently low affinity for transport/anchoring factors or binding of an inhibitory factor—remain viable hypotheses.

EGL protein preferentially binds to active forms of the TAS

We synthesized EGL protein by coupled in vitro transcription and translation and tested its binding to RNA transport signals with an assay similar to one previously reported [14]. The RNAs were immobilized on streptavidin magnetic beads via a 3’ aptamer [22,23], and the aptamer alone was tested in parallel as a background control. EGL protein binds to the fs (1)K10 TLS RNA, but binding is reduced when bulges in the stem loop are removed (TLS^ΔAC) [14]. Consistent with this previous result, in our assays EGL binding to TLS^ΔAC was reduced to background levels (i.e., to the binding shown to aptamer alone; Fig 3A and 3B). TLS binding was, therefore, used as a reference point, and the results are expressed as a fraction of that value (Fig 3B).

Overall, EGL binding to SL2a, both wild type and variants, showed a good correlation with transport and anchoring activity. EGL did not bind intact SL2a above background. By contrast, EGL bound robustly to the Δ550–597 tl version of SL2a. Addition of the 539–540 mutation (in SL2aΔ550–597 tl^mut), which disrupts TAS activity in vivo (see Fig 1A and 1B), reduced binding by EGL to background levels. The isolated TAS tl transport signal was also strongly bound by EGL, and addition of the 539–540 mutation (in TAS tl^mut) reduced binding to background. EGL binding to the isolated TAS tl with an extended stem (TAS tl+clamp) was, on average, substantially higher than to the aptamer alone. Although the statistical analysis did not confirm this difference, the in vivo activity of this RNA suggests that the binding is meaningful.

Genetic tests provided further support for the notion that EGL mediates activity of the TAS. First, reducing egl gene dose lessened the effects of enhanced TAS activity of the osk 3’Δ550–597 tl mutant. Whereas the osk 3’Δ550–597 tl mutant in egl⁺ mothers produced all strongly bicaudal embryos, mutating one copy of egl resulted in a substantial shift towards wild type (Fig 3C). Second, increasing egl dose mimicked the effects of enhanced TAS activity. Expression of a UAS-egl transgene under control of the GAL4:VP16-nos driver is known to produce some bicaudal embryos, with osk mRNA inappropriately enriched in their anterior region [24]. To ask if the osk mRNA in ovaries with excess EGL was mislocalized in the same manner as from uninhibited TAS activity, we expressed UAS-egl using the matalpha4-GAL-VP16 driver. In the ovaries, osk mRNA was retained at the anterior of late stage 9 egg chambers, much like the localization defect of the osk 3’Δ550–597 tl mutant (Fig 3D). All of the resulting embryos were bicaudal (Fig 3C).

Taken together, our in vitro and in vivo results are consistent with a role for EGL in transport and anchoring of osk mRNA at the oocyte anterior via binding to the TAS.

The predicted SRSs in the osk 3’ UTR bind to STAU

A candidate to inhibit TAS activity in the context of SL2a is STAU. Notably, SL2a includes two predicted binding regions for STAU [19], where one is removed in the osk 3’ Δ550–597 tl mutant in which we have shown that inhibition of TAS activity is alleviated.

To define presumptive STAU binding sites, Laver et al. [19] used an RNA coimmunoprecipitation (RIP) strategy, isolating mRNAs associated with STAU in Drosophila embryos and then carrying out a computational search for features shared by bound transcripts relative to co-expressed unbound transcripts. They identified several classes of STAU Recognized Structures (SRSs), which consist of variants of duplex regions within stem loop structures. Multiple SRSs are predicted in the osk 3’ UTR [19], and all are overlapping versions of what we call SRSs 1–5, which reside in four stem loop structures (SL1, SL2a, SL2b and SL3; Fig 4A and 4B). As a prelude to considering the possible role of STAU in modulating TAS activity, we assessed whether SRSs are bona fide STAU binding sites, using the osk mRNA as a test case. Our approach was to mutate the SRSs, first altering bases in one strand of the duplex to disrupt an SRS, then modifying the initial mutant with compensatory changes to restore the duplex and the SRS (but now with a different sequence; Fig 4B). With these pairs of mutants, a RIP assay was used to test for STAU binding, and osk transgenes were used to ask if they recapitulate the effects of stau mutants on osk regulation in vivo.

For the RIP binding assay, versions of osk mRNA 3’ UTRs (Fig 4B) were fused to the Firefly luciferase open reading frame, and then expressed from DNAs transfected into Drosophila S2 cells (Renilla luciferase was used as a transfection control) together with 3xFLAG-tagged STAU. For the reason addressed below, the osk 3’ UTRs had all SRSs mutated, or just SRSs 1 and 5. After RIP with FLAG-STAU, co-IPed RNA levels were measured by RT-qPCR and double normalized as described in the Materials and methods. The results are shown in Fig 4C. Wild-type osk 3’ UTR was about three-fold enriched in the co-IPed RNA. Mutation of SRSs 1 and 5 significantly reduced STAU binding, while mutations of all SRSs together showed the greatest reduction. Inclusion of compensatory changes in the SRSs to restore duplex formation also restored binding to STAU. These results argue that the SRSs predicted in the osk 3’ UTR are bona fide STAU binding sites.

STAU-independent consequences of mutating SRSs

Next, the above SRS mutations were introduced into osk transgenes for testing in the osk RNA-null background. A primary goal was to ask if reduced STAU binding mimics the effects of stau mutants on osk mRNA regulation, thereby confirming that the SRSs mediate the action of STAU on osk mRNA. In addition, we wanted to ask if SRS mutations in SL2a could be used to test the model that STAU binding close to the TAS inhibits its activity. The answer to the latter question was no, and we address the underlying cause first because it informs the interpretation of SRS mutant phenotypes.

When all SRSs in osk mRNA were mutated (osk SRS all^mut), no eggs were laid (Fig 5A); this is not a phenotype of stau mutants [25] and so at least some SRS mutations must have effects not attributable to loss of STAU binding. Most egg chambers of osk SRS all^mut failed to progress beyond stage 8 or early stage 9 (Fig 5B). The arrest was rescued by compensatory mutations (in osk SRS all^comp)(Fig 5B), with a substantial increase in egg laying (Fig 5A).

The arrest of oogenesis from mutation of all SRSs is readily explained. Although the SRS mutations did not change the sequence of the TAS in SL2a (Fig 4B), loss of base pairing in both proximal and distal portions of the SL2a stem could alter proper folding of the signal. TAS activity is required for osk ncRNA function [11], and disruption of osk ncRNA function results in arrest of oogenesis [6]. RNA folding predictions support this interpretation: considering folding of the entire SL2 region, when SRSs 2 and 3 were both mutant (in the osk SRS all^mut transgene) the TAS (i.e., the consensus structure of S1 Fig) did not appear in any predicted fold whose ΔG was within 10% of the most stable version (S2 Fig).

To further explore effects of SRS mutants on STAU-independent disruption of oogenesis, we tested additional mutants. The outer SRSs, 1 and 5, lie within predicted stem loop structures not previously implicated in any aspect of osk mRNA regulation or function, and mutation of both had no effect on egg laying (Fig 5A).

Testing transgenes with individual SRSs mutated reinforced the conclusion that arrested oogenesis for the osk SRS all^mut transgene came from changes within SL2a. Only from mutation of SRS 3 (in SL2a) was there a significant reduction in rate of egg laying (Fig 5A). For the SRS 3 mutant, the overall folding stability of SL2 was reduced, and the TAS structure was not necessarily present in the most stable fold (S2 Fig). Combining both SRS 2 and 3 mutations (in osk SRS 2,3^mut) arrested oogenesis (Fig 5B) and eliminated egg laying (Fig 5A). Consistent with these defects, folding predictions showed loss of the TAS structure (S2 Fig).

SRS 4 lies within SL2b, the location of the oocyte entry signal (OES) [10], which is also required for osk ncRNA activity [7,11]. Based on the properties of deletion mutants in SL2b [11], the SRS 4 mutation would not be predicted to have a substantial effect on the OES contribution to osk ncRNA activity. Furthermore, even suboptimal folds with the SRS 4 mutant did not affect formation of the TAS structure in SL2a (S2 Fig). Consistent with the absence of any substantial predicted effect on either TAS folding or OES activity, egg laying remained strong for the SRS 4 mutant (Fig 5A).

Disruption of TAS activity from mutation of SRSs 2 and 3 ruled out use of these mutations to test any model for how TAS activity might be inhibited. It is important to emphasize that the defects of SRS 2 and 3 mutants can be fully explained by indirect effects on TAS folding, and there is no reason to believe that STAU binding is required for TAS activity; we argue below that STAU binding inhibits TAS activity.

SRS phenotypes that mimic the stau mutant phenotype

SRS mutants that did not strongly disrupt TAS activity could be tested for effects on osk mRNA distribution in the later stages of oogenesis, and thus could be compared to the effect of mutation of stau. In stau mutants the level of osk mRNA at the posterior of the oocyte is greatly reduced, and there is significant retention of the mRNA at the anterior of the oocyte [16–18] (Fig 6A). We measured both posterior localization and degree of anterior retention. Mutation of SRSs 1 and 5 together caused a significant reduction in posterior localization of osk mRNA within stage 9 and 10A oocytes (Fig 6A and 6B), with substantial levels concentrated in cortical regions at or near the anterior (Fig 6A, 6D and 6E; the strategy for anterior RNA quantitation is shown in Fig 6C). Parallels with the stau mutant phenotype extended to loss of posterior pattern elements in embryos (S3 Fig) and reduced OSK protein accumulation (S4 Fig). Each of these defects was rescued by compensatory mutations in SRSs 1 and 5 (Fig 6A, 6B, 6D, 6E, S3 and S4 Figs). Similarly, the transgene in which all SRSs were mutated together with compensatory changes had significant posterior localization of the mRNA and close to wild-type embryonic body patterning (Fig 6B and 6E and S3 Fig).

Mutation of any individual SRS also substantially reduced the amount of osk mRNA localized to the posterior pole of the oocyte (Fig 6B) and interfered with body patterning (S3 Fig). For mutants of SRSs 1, 4 or 5, the reduction in posterior localization was accompanied by anterior retention of the mRNAs (Fig 6E), as would be expected based on the observed stau mutant phenotype. By contrast, there was no anterior enrichment for mutants of SRSs 2 or 3. This could reflect some diversification in SRS function, but is more simply explained by reduced anchoring since it is mutation of these SRSs that interfered with folding of the TAS (S2 Fig), and any reduction in TAS cortical anchoring activity would reduce the degree of anterior retention.

The striking parallels between SRS mutant and stau mutant phenotypes reinforce the conclusion that the osk mRNA SRSs—all of them—mediate the action of STAU, although not necessarily all by the same mechanism. The position of two SRSs closely flanking and overlapping with the TAS (see Fig 4B) supports the notion that one mode of STAU action may be to regulate TAS activity.

STAU inhibits activity of SL2a in both RNA transport and cortical anchoring

Although the SRS mutants per se were not useful to test the model that STAU exerts an inhibitory effect on TAS activity, we could instead ask if TAS activity is affected in stau mutant ovaries. Notably, STAU is highly concentrated in the oocyte, with only low levels detectable in nurse cells [25]. Consequently, STAU might be expected to have a more limited effect on the process occurring primarily within the nurse cells (i.e., transport to the oocyte) and a stronger influence on cortical anchoring within the oocyte.

To test the effects of loss of STAU on RNA transport we took advantage of the low transport activity of isolated SL2a, which simplifies detection of even a small increase. The reporter transgene with SL2a was compared for oocyte enrichment in wild-type and stau mutant backgrounds. Transport into the oocyte was improved in homozygous stau mutant ovaries, and inclusion of a rescuing stau⁺ transgene significantly reversed this effect (Fig 7A).

To test the effects of loss of STAU on cortical anchoring, an active TAS is required. Two versions of SL2a were used. One had SL2a together with SL2b (in SL2) and thus contains SRSs 2–4. The second had SL2a in the Δ550–597 tl form (see Fig 1A) to enhance transport and anchoring activity. This version retains SRS 2 in the proximal stem.

As a measure of cortical anchoring, RNA intensity was measured along vectors 10 μm long and 16 μm wide extending from the anterior lateral cortex into the interior of the oocyte (Fig 7C). Representative images and traces obtained from them are shown in Fig 7D. The fraction of RNA in the most cortical 2.5 μm, relative to the sum of RNA along the 10 μm vector, serves as a measure of cortical anchoring efficiency. For both forms of SL2a, the cortical anchoring efficiency increased significantly in the stau mutant (Fig 7B), consistent with the more prominent cortical concentration visible in the images (Fig 7D). Just as observed for transport activity, addition of a stau⁺ transgene significantly reversed the effect of the stau mutation (Fig 7B). Taken together these results lead us to conclude that STAU has an inhibitory effect on the anchoring activity of the TAS.

Discussion

We have shown that EGL binds to the TAS element of the osk mRNA’s 3’ UTR. Just as for the fs(1)K10 TLS paradigm of a regulatory element bound by EGL, active forms of the TAS mediate not only transport to the oocyte but also cortical anchoring once inside the oocyte. Previous work is conflicted on the role of the EGL/BICD system for transport of osk mRNA from the nurse cells to the oocyte. Coimmunoprecipitation studies have shown association of EGL with osk mRNA [26], and certain mutations in BicD alter the localization of osk mRNA [17]. However, osk differs from multiple mRNAs transported by the EGL/BICD system in failing to undergo strong apical localization when injected into early stage embryos [10,13], a difference that can now be understood (below).

The minimal TAS is active and is bound by EGL. However, in the context of the isolated SL2a stem loop domain (as opposed to the complete osk mRNA), the TAS has little transport and anchoring activity and is not bound by EGL above background. We previously proposed that weak association of transport factors with the signal in SL2a would facilitate transfer of the mRNA to other factors for the subsequent step of posterior localization [11]. Now, with evidence that the TAS mediates both transport and anchoring, the notion of a need to modulate TAS activity becomes more compelling, as persistent anchoring would unquestionably interfere with posterior localization.

Evidence that TAS activity is regulated came from the discovery that an osk mutant mRNA is mislocalized in a manner much like an osk mRNA to which the TLS was added. Because the TAS itself was not altered, the mutant appeared to be defective in an inhibitory effect on TAS activity. Experiments detailed here with reporter transgenes comparing wild-type and mutant versions of SL2a have confirmed that the latter is relieved from inhibition of TAS activity, for both transport and anchoring. Efforts to assign the inhibitory effect to a specific feature of SL2a have shown that no single difference is solely responsible; instead, the several differences in the mutant have effects. One of these differences, the deletion of a terminal region of the SL2a stem, results in loss of one of two predicted binding sites in SL2a for STAU, a protein implicated in osk mRNA localization.

The presence of predicted STAU binding sites, SRSs, in close proximity to or overlapping with the TAS in SL2a, suggested a possible role for STAU in regulating TAS activity. To explore this possibility we needed first to determine if the predicted SRSs [19] are bona fide STAU binding sites. Binding studies with osk RNAs with altered SRSs, and analysis of the behavior of the same mutants in vivo, validated STAU binding. While in this study we have only tested SRSs in the osk mRNA, validation of the STAU binding site predictions raises confidence in their use for analysis of the extent and diversity of STAU function.

Mutation of SRSs that are distant from the stem loops acting in the transport of osk mRNA to the oocyte mimicked the effect of stau mutations on osk mRNA localization. There was no decrease in transport of the mRNA to the oocyte (S5 Fig), but within the oocyte, localization to the posterior was substantially reduced and a fraction of the mRNA remained at anterior and cortical regions. These defects, rescued by compensatory changes that restore RNA duplexes that comprise SRSs, represent a weaker version of how osk mRNA is affected in stau mutant ovaries, as might be expected for partial loss of STAU binding to the mRNA. Furthermore, the reduction in posterior localization from mutation of SRSs not implicated in regulating transport or anchoring signals (and not close to them in the primary RNA sequence) is consistent with a model in which STAU plays a role in facilitating directed movement of the mRNA to the posterior pole [25].

We were unable to use osk mRNAs with altered SRSs to evaluate a possible additional role for STAU in regulating TAS activity: the mutations are predicted to destabilize the SL2a structure, including folding of the TAS. Instead, we asked if absence of STAU would relieve inhibition of TAS activity, which is normally strong in the context of the complete SL2a fused to a reporter mRNA. Use of the reporter mRNA eliminated the complication, when testing osk mRNA, of being unable to distinguish between two events: release from anchoring at the anterior cortical regions, and directed posterior localization, which the reporter mRNA does not undergo. We found that STAU does contribute to inhibition of TAS activity, both in transport and in cortical anchoring. How STAU inhibits TAS activity is unknown, but with two SRSs near to or overlapping the TAS, an inhibitory effect on EGL binding is plausible. Demonstration of a specific molecular mechanism may emerge from biochemical reconstructions with purified STAU and EGL, which are beyond the scope of this report.

Evidence that STAU inhibits TAS anchoring activity supports the notion that STAU plays two roles in osk mRNA localization. In addition to a possibly direct role in posterior movement, consistent with the behavior of osk mRNA with mutations in SRSs 1 or 5, STAU also acts to remove or relax the tension between competing machineries: the anchoring machinery working to hold the mRNA in place at the anterior where it entered the oocyte, and the posterior localization machinery working to move the mRNA to the posterior of the oocyte. The effect of stau mutants on localization of endogenous osk mRNA—anterior retention and loss of posterior localization—is concordant with both roles. A related version of a role for STAU in releasing osk mRNA from the transport machinery was suggested previously [25] in the context of explaining why reducing stau activity enhances the defects of the dominant BicD¹ mutant [17,25]. Biochemical properties of BICD and of the BicD¹ mutant, obtained more recently, are illuminating [24,27–29]. BICD acts to link a cargo—in this case EGL and associated RNA—to Dynein for transport along microtubules. BICD binding to Dynein is autoinhibited by interaction between the coiled coil domains CC3 and CC2/CC1 of BICD. Cargo binding to CC3 causes a rearrangement of CC3, altering its interaction with CC2/CC1 which becomes available for Dynein binding. The BicD¹ mutation appears to disrupt heterotypic core packing of the CCs, removing the autoinhibitory interaction and promoting Dynein binding, but only when cargo is bound [24]. Thus, in BicD¹ mutant ovaries the EGL/osk mRNA cargo is too consistently bound to the transport and anchoring machinery, interfering with the handoff to the posterior localization machinery. If STAU acts to displace the transport machinery, as we suggest, then reducing the level of STAU will exacerbate the BicD¹ phenotype, as observed [25].

Inhibition of TAS activity by STAU may be concentration-dependent: loss of STAU has a modest effect on transport from nurse cells, where STAU is present at very low levels, while loss of STAU has a greater effect on anchoring in the oocyte, where STAU is abundant. This interpretation explains the weak apical localization of osk RNA in early embryos, relative to other RNAs with stem loop structures bound, or potentially bound, by EGL [10,13]. In early embryos, STAU, while enriched at anterior and posterior poles, is present at significant levels throughout [25]. Thus, STAU could bind to osk RNA throughout the embryo and inhibit its apical transport and its anchoring.

Although our evidence supports the model of STAU acting to inhibit the activity of the TAS, two observations argue that this is not the only means by which the TAS is regulated. The changes in osk 3’Δ550–597 tl substantially alleviate inhibition of TAS activity. While this effect may be due in part to the loss of SRS 3 in the distal stem of SL2a, smaller deletions that also disrupt SRS 3 (e.g., osk 3’Δ559–588 tl) did not have such a dramatic effect on TAS activity. Thus, the larger deletion appears to relieve inhibition of TAS activity in more than one way. Second, removing STAU only modestly improves transport activity of the TAS in the context of SL2a, while the minimal, uninhibited forms of the TAS have higher transport activity. It is notable that the combined SL2a and SL2b, in SL2, provide robust transport, well beyond the low activities of either stem-loop alone and suggesting a synergistic effect. It would not be surprising if interplay between undefined regulatory elements in the different stem loops serves both to enhance transport and to inhibit anchoring.

EGL binds preferentially to RNA duplexes that adopt the A’ form, which facilitates minor groove contacts [14,30]. STAU is predicted to bind to duplexes with a small number of non-Watson-Crick and unpaired bases (i.e., bulges) [19] and a recent structural analysis of human STAU1 binding to part of the Arf1 mRNA suggests specific base contacts via the minor groove [31]. Because both proteins bind duplex RNA, overlap in their binding sites as found in SL2a would not be unusual. Perhaps STAU proteins act by modulating the activity of other proteins that bind duplex RNA, with EGL being only one example of this phenomenon. Such a role would help explain the wide variety of post-transcriptional control mediated by STAU proteins, including transport, translation and decay of mRNAs, as well as modulation of microRNA activity [18,32–35].

Materials and methods

Flies and transgenes

Genomic osk transgenes were based on a genomic fragment that fully rescues osk null mutants [16] and made by phiC31 transgenesis to the attP site on chromosome II at 51D (in Bloomington stock center strain 24483). Those from prior work were inserted on chromosome II at 51C (in Bloomington stock center strain 24482), which provides a similar level of expression. The genomic osk transgenes were tested in an osk RNA null combination, typically osk^N homozygotes but in some cases using Df(3R)osk [36] or osk⁰ [7] alleles. The osk^N allele was generated by CRISPR/Cas9 methodology, and carries a deletion removing much of the osk gene (positions 3R:8,936,316–8,967,424 in r6.34). All Drosophila genomic sequence coordinates were obtained from FlyBase [37].

The stau^C mutant was generated by CRISPR/Cas9 methodology, and carries a deletion removing almost the entire coding region (positions 2R:18,119,804–18,124,777 of r6.36 of the genome sequence). The rescuing stau⁺ transgene included genomic sequences positions 2R:18,116,718–18,128,607, r6.36.

Reporter GFP transgenes are derivatives of UAS-osk::GFP, which includes a 5’ portion of the osk gene and coding region (osk mRNA coordinates 1–534, including the first 173 amino acids of Long Osk) [38]. The matalpha4-GAL-VP16 driver [39] inserted on chromosome 3 (Bloomington Drosophila stock center stock #7063) was used for expression of UAS transgenes, all made by P element transgenesis.

The UAS-egl transgene was from Helen Salter and Simon Bullock [24] and was used in combination with the matalpha4-GAL-VP16 driver.

Mutations or additions to transgenes were made using synthetic DNA fragments (gBlocks; Integrated DNA Technologies).

Egg laying assays were performed as described [11].

Detection of RNAs and proteins

RNA levels were determined by RT-qPCR. RNA was extracted from whole ovaries using the mirVana isolation kit (Ambion/Thermo Fisher Scientific). Reverse transcription using 1 μg RNA was performed with Sensifast cDNA kit (Bioline) with random hexamer and oligo d(T) primers following the manufacturer’s protocol. qPCR on cDNA samples was performed in triplicate on ViiA7 (Applied Biosystems/TF) with Sensifast SYBR LoRox qPCR Supermix according to the manufacturer’s protocol for two-step cycling with 40 cycles and a 25 second annealing/elongation step for both osk and RpL32 mRNAs. Primers with comparable lengths, melt temperatures and G/C content were selected from the FlyPrimerBank database (https://www.flyrnai.org/flyprimerbank) (osk: ATGACCATCATCGAGAGCAACT and GTGGCTCAGCAATATGGCG; RpL32: GCCCAAGGGTATCGACAACA and GCGCTTGTTCGATCCGTAAC). A five-log-order standard series of a control osk transgene with wild-type activity in an osk RNA null background served as a control for copy number and for plate reaction efficiency. A comparable dilution series was made by pooling all samples to be run on a plate, and the efficiency was compared to that of the standard series. All efficiencies were between 90–110%, and efficiencies from the sample pool were within 5% of the standard series. Cycles to threshold were calculated in QuantStudio (Thermo Fisher Scientific), and the RNA level of osk relative to RpL32 for each sample was normalized to respective osk⁺ transgene controls with matched efficiency by the 2^-ΔCt method, dividing the average of sample biological replicates by that of the control [40]. At least three biological samples were tested for each mutant, except osk 3’ unp and osk 3’ unpall, for which one sample was dramatically different from all the others tested and so was excluded. Melt curves were screened for multiple species and consistent melt temperatures, and technical replicates with a deviation of more than 0.5 cycles to threshold were rejected. RNA levels for the transgenes first used in this report are presented in Table 1. There are three instances in which the levels differed from the osk⁺ control by more than two-fold: osk 3’ Δ550–597 tl, osk 3’ Δ550–597 bl and osk 3’ unpall, with each at higher levels than the osk⁺ control. Although elevated levels of the first two of these mutant mRNAs may have contributed to the severity of their body patterning defects, the changes in mRNA distribution (the phenotype most relevant to the conclusions) cannot be attributed to higher levels. The transgenes were present in single copies (as was the osk⁺ control), and their levels were only slightly above that of endogenous osk in wild-type ovaries where two copies of osk are present. Moreover, increasing the dosage of wild-type osk to substantially higher levels does not result in similar anterior accumulation of osk mRNA [5]. Most importantly, the key conclusion from these transgenes, that the cortical anchoring activity of the TAS in SL2a is normally subject to inhibition, was confirmed by experiments with reporter transgenes. For the third mutant mRNA present at the higher level (but effectively the same as osk⁺ in wild-type flies), osk 3’ unpall, there was no observed mislocalization of the mRNA. Any effect of the mutation on causing inappropriate expression of OSK protein would have been enhanced by higher mRNA levels yet there was only a very low level of ectopic osk activity.

RNA distributions were detected by in situ hybridization using two types of probes: tiled short DNA oligonucleotides (smFISH) (Figs 1B, 2B, 3D, 6A, 7A, 7B and 7D) or RNAs synthesized by in vitro transcription (Fig 1E and S3 Fig). For smFISH the tiled oligonucleotides were 3’-end labeled with Quasar 670 fluorophore (LGC Biosearch Technologies) and used at 1.5 nM. Assays were performed as described [41]. Immunodetection of OSK protein in fixed ovaries (S4 Fig) was as described [42]. Samples were imaged with a Nikon C2+ laser scanning confocal microscope. For all imaging experiments the samples were obtained from at least five flies, typically many more. Imaging experiments to detect mRNAs by in situ hybridization were performed in groups, with all samples from a single comparison set imaged in the same session with identical confocal settings. The sole exception is in Fig 6A, where the panel showing the distribution of osk mRNA in a stau mutant was obtained from a separate experiment; this image was not used for quantitation. Quantification of in situ hybridization data was done with Adobe Photoshop, FIJI or Nikon NIS Elements software, using different strategies for different types of experiments. To analyze anterior osk mRNA levels in Fig 3D, all images were copied to a single file then merged to one layer, threshold for the green (RNA) channel was set to 12 (sufficient to eliminate all background signal while retaining a high degree of sensitivity), and each late stage 9 egg chamber was scored for presence or absence of any signal above threshold at each of the two anterior/lateral junctions in the oocyte, producing scores of 0, 1 or 2. FIJI was used to quantitate the degree of anterior oocyte retention in Fig 2B. Areas of similar size were traced at each anterior/lateral junction of individual oocytes following the outline of the oocyte and extending about 5% of the length and width of the oocyte, and a single larger area was traced in the center of the oocyte away from the cortex. Average signal intensities were measured for each area, the values for the two anterior regions were averaged, and the value for the central area (background) was subtracted. All other analyses used Nikon NIS Elements.

To quantitate the degree of oocyte enrichment in early-stage egg chambers, regions of interest (ROIs) of nurse cell cytoplasm and oocyte cytoplasm were drawn. Average signal intensities within the ROIs were calculated from total pixel intensities divided by ROI areas. For quantitation of levels of RNA in the posterior region of stage 9 and 10A oocytes (Fig 6C), the Nikon Elements ROI auto-detect function was used to outline the posterior signal, with background (measured in follicle cells where osk is not expressed) subtracted. As an estimate of the fraction of RNA in the anterior region of oocytes (Fig 6D), the lateral cortex of each oocyte (not including the anterior boundary that abuts the nurse cells) was traced, yielding data sets as shown in Fig 6B. The sum of the signal in the first 15% and last 15% of each trace (the anterior lateral regions) was divided by the sum of the first and last 15% plus the central 30% (the posterior region) of each trace to give the value shown in Fig 6D.

RNA-binding assays with EGL protein

For EGL protein expression, the egl in vitro transcription/translation template was PCR amplified from a linearized plasmid template that contains the egl ORF using Phusion HF polymerase (NEB) according to the manufacturer’s instructions with a final concentration of 3% DMSO to promote denaturation. PCR cycling conditions were: denaturation at 98°C for 10 sec, 34 amplification cycles with annealing at 50°C + 0.5°C/cycle and extension at 72°C for 1 min, and a final cycle of 72°C for 10 min. The primers introduce a T7 promoter and a Kozak consensus sequence at the 5’ end and a stop codon and a poly(A) tail at the 3’ end (Egl F: 5’ CGA TTT GAA TTC TAA TAC GAC TCA CTA TAG GGA ACA GCC ACC ATG GAG TCC ATG GAG TAC GAG ATG GCA 3’; Egl Rev: 5’ TAT ATA GGA TCC TTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TTA TGT GG GAGA CACA CG CTT CGC GGG 3’). The primer concentration in the PCR reaction was 100 nM to limit amplification of PCR products that were not full-length. PCR products were purified using a MinElute column (MinElute Reaction Cleanup Kit, Qiagen) and quantitated using a Nanodrop.

³⁵S-methionine-labeled proteins were produced in rabbit reticulocyte lysates using a T7 quick-coupled transcription/translation (TNT) system (Promega) according to the manufacturer’s instructions, using 400–500 ng of purified PCR product per 50 μl reaction. To estimate protein yield, an aliquot of synthesized protein was passed over a Zeba Spin desalting column (Thermo Fisher Scientific) to remove unincorporated methionine and counted in a scintillation counter against a serial dilution of ³⁵S- methionine. Protein yield was found to be in the femtomolar range. Proteins were analyzed in 4–20% Mini-PROTEAN TXG gels (Bio-Rad), dried, exposed to a PhosphorImager screen (Fuji), scanned in a Typhoon Imager (GE) and analyzed using Quantity One software (Bio-Rad).

To prepare templates for transcription of RNA substrates, sequences were PCR amplified with primers that append a 5’ T7 promoter and cloned into the EcoRI and BamHI sites of the pUC-19 vector, to which the S1mx4 aptamer [23] was added using the PstI and HindIII sites, respectively. The S1mx4 aptamer by itself was cloned into pBluescript KS + (5’ PstI, 3’ HindIII). RNAs, with 4 copies of the S1mx4 aptamer at the 3’, or the S1mx4 aptamer by itself, were generated by in vitro transcription (Megascript T7 kit, Invitrogen) from HindIII linearized templates, and purified using Zymo RNA Clean and Concentrator columns (ZYMO Research) according to instructions and concentration determined by measuring using the Nanodrop.

Before immobilizing RNAs on magnetic streptavidin beads, they were incubated in 1x DXB buffer (30 mM Hepes at pH 7.3, 50 mM KCl, 2.5 mM MgCl₂, 250 mM sucrose and 1 mM DTT, 2 μg of RNA in a 20 μl reaction) at 56°C for 5 min, followed by 10 min at 37°C and 15 min at 20°C to allow refolding [23]. The refolded RNA was bound to 50 μl of washed magnetic Dynabeads (Thermo Fisher Scientific) in 100 μl of 1x DXB buffer and 0.01% NP-40 (DXB+NP-40) and RNAse inhibitor (SUPERaseIn, Thermo Fisher Scientific) in DNA LoBind tubes (Eppendorf) in a Thermomixer (Eppendorf) at 4°C for 2 hours at 1000 rpm. For a given set of experiments, the magnetic beads were washed in one batch (3 washes with Buffer A: DEPC treated 0.1M NaOH and 0.05 M NaCl, 3 washes with DEPC treated 0.1 M NaCl, and 3 washes with DXB+NP-40) and distributed into individual tubes before the addition of the different RNAs.

After binding, the unbound RNAs were removed, and streptavidin-bound RNAs were rinsed twice with DXB+NP-40 on the magnetic rack, after which in vitro transcribed/translated EGL protein (10–12.5 μl of a 50 μl in vitro transcription/translation reaction per RNA) was added in 100 μl DXB containing 1x EDTA-free protease inhibitor (Roche) and RNAse inhibitor and incubated on a Thermomixer for 90 min at 1000 rpm. Unbound RNAs were run on an agarose gel to ascertain even input.

After binding of the protein to the affinity-bound RNAs, beads were washed 6 times with DXB+NP-40 buffer on the rack, after which the bead- bound protein was boiled off by adding 100 μl of 1x Laemmli buffer and incubating for 15 minutes on a Thermomixer at 100°C and 1000 rpm. Tubes were spun briefly before loading sample on a protein gel to remove particulate matter. An aliquot of the EGL protein used for the binding experiment was run as an input control.

To establish the level of background binding an aptamer-only control was used. This reveals the level of EGL bound to both aptamer and beads. Although not included in Fig 3 we also tested, in separate experiments, EGL binding to beads alone (a no RNA control). Typically, observed binding of EGL to the beads in the absence of RNA was less than 10% of the level of binding to beads plus aptamer.

RNA structure predictions

Predictions of RNA folding were performed in the Mfold Web Server (http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form) [43].

Reagents for RNA co-immunoprecipitation (RIP) assays

Four plasmids were used. The first expressed an N-terminal 3xFLAG-tagged STAU protein (3xFLAG-STAU). The second expressed Firefly luciferase reporter mRNA with the wild-type and mutant versions of the osk 3’ UTR described above (Firefly luciferase-osk 3’ UTR). The third expressed Renilla luciferase and served as a transfection control (Renilla luciferase). The fourth plasmid was pSP72, a transfection carrier DNA.

Luciferase reporters were cloned into pRmHa3 [44] and, thus, were under the control of the metal-inducible metallothionein promoter. The wild-type and mutant osk 3’UTR DNA constructs were inserted into the Firefly luciferase reporter vector at the BamHI and SalI restriction sites. All osk 3′ UTR constructs were truncated at the 3’ end, with the final 68 nt of the osk mRNA removed. 3xFLAG-STAU was derived from pAc5.1/V5-His (Thermo Fisher Scientific), which carries the Actin5C promoter. To produce 3xFLAG-STAU, wild-type stau isoform C was amplified by PCR from whole embryo 0–3 hours extract and inserted into the vector at the EcoRV and XbaI restriction sites.

Drosophila S2 tissue culture cells were maintained at 25°C in Express Five SFM (Fisher Scientific) containing 100 units/mL penicillin, 100 μg/mL streptomycin and 16mM glutamine. A mixture of 250 ng Firefly luciferase-osk 3′ UTR plasmid, 50 ng Renilla luciferase plasmid, 250 ng 3xFLAG-STAU plasmid was transfected into 4 mL of S2 cells at a density of 1.5 x 10⁶ cells/mL using 6 μL X-tremeGENE 9 DNA Transfection Reagent (Roche), according to the manufacturer’s instructions. The expression of luciferase reporters was induced 3 hours post transfection through the addition of copper sulfate to a final concentration of 0.5 mM.

72 hours post-transfection S2 cells—resulting in a total of 6 x 10⁶ cells/mL—were harvested, incubated in lysis buffer (150 mM KCl, 20 mM Hepes pH 7.4, 1 mM MgCl₂, protease inhibitor, DTT, and 0.3% Triton X-100) for 25 minutes on ice (4°C), then centrifuged for 15 minutes 13000 rpm 4°C, and supernatant was recovered. The protein concentration of the lysate was determined with a Bio-Rad Protein Assay Dye Reagent. The lysate was diluted to 8.5 μg/μL with lysis buffer.

RNA co-immunoprecipitation (RIP)

Each IP used 5 μL of anti-FLAG M2 beads, which were washed four times with lysis buffer (150 mM KCl, 20 mM Hepes pH 7.4, 1 mM MgCl₂, protease inhibitor, DTT, and 0.1% Triton X-100). 90 μL of diluted, cleared supernatant was added to each tube of beads and incubated for 3 hours at 4°C with end-over-end rotation. Beads were washed five times with lysis buffer (150 mM KCl, 20 mM Hepes pH 7.4, 1 mM MgCl₂, 0.1% Triton X-100, protease inhibitors, DTT). 50 μL of lysis buffer was added to the beads. The bead volume was then split in half: (1) for RNA isolation with TRIzol and (2) for protein quantification. In addition, 50 μL of extract was saved to measure RNA ‘input’ and 10 μL for ‘input’ protein.

A Western blot was performed on the lysate extract of the input and RIP to quantify the efficiency of IP of 3xFLAG-STAU by anti-FLAG M2 beads. 10 to 15 μL of lysate from RIP was resolved via SDS-PAGE. The proteins were transferred to PVDF membrane, which was blocked at room temperature for 1 hour with 2% milk in PBST (1x PBS + 0.1% Tween20). The blots were incubated overnight with anti-FLAG M2 antibodies (Sigma-Aldrich) at 4°C and then incubated with HRP-conjugated secondary antibody (1:5000) at room temperature for 1 to 3 hours. The blots were developed with ECL Plus detection reagents (MilliporeSigma Luminata Crescendo) and then imaged and quantified using the VersaDoc Imaging System (Bio-Rad). The relative levels of 3xFLAG-STAU from RIP were determined using a standard curve.

RNA was isolated from RNA co-immunoprecipitation by adding 9:1 of TRIzol reagent (Invitrogen) to bead volume and the RNA was purified according to manufacturer’s instructions. The isolated RNA was quantified using a NanoDrop Fluorospectrometer.

The RNA was treated with DNAse I, according to Invitrogen’s instructions with the following minor modifications. 1 μL of 25 mM EDTA was substituted with DEPC-treated water, 2.5 μg of RNA ‘input’ and 8 μL of RNA from IP were used instead of 1 μg of RNA. In addition to the manufacturer’s protocol, the DNAse-treated RNA was heated at 80°C for 4 minutes. The RNA was used to generate cDNA through reverse transcription with SuperScript IV reverse transcriptase (Invitrogen) and random hexamers (Thermo Fisher Scientific) by following the manufacturer’s instructions. The cDNA was subjected to quantitative real-time PCR using the SensiFast SYBR PCR mix (Bioline) and primers against the Firefly and Renilla luciferase ORFs.

Relative levels of the Firefly and Renilla transcripts were determined using a standard curve. The STAU-binding enrichment was calculated by first normalizing Firefly luciferase-osk 3′UTR expression to Renilla luciferase expression from IP, then by normalizing to input, and finally by normalizing to Firefly luciferase-only vector.

Numerical data

Numerical data underlying all graphs in the figures is provided in S1 File.

Statistical methods

Reproducibility was confirmed by performing independent experiments. Biochemical experiments were repeated a minimum of three times. Imaging experiments, which were performed at least twice, involved examination of multiple individual egg chambers in each experiment. Here, repetition served to reveal any technical problems, and the large number of individual egg chambers scored in each experiment ensured consistency and reproducibility. Egg laying experiments were performed at least three times. Rates of egg laying often show circadian variation, but because each experiment consisted of egg collections over several days, this source of variation was minimized. The experiments were not randomized, and no statistical method was used to predetermine sample size. One-way ANOVA was used to ask if there were significant differences among data sets with three or more variables. For post hoc analyses, Shapiro-Wilk normality tests were first performed. If the test failed to reject normality, Student’s t tests were used for post hoc analysis. If normality was rejected, Wilcoxon rank sum tests were used for post hoc analysis. The particular tests used are indicated in the figure legends.

Supporting information

S1 Fig [pdf]
Phylogenetic comparison of the SL2a transport and anchoring signal (TAS).

S2 Fig [a]
Effects of SRS mutations on predicted folding of SL2.

S3 Fig [pdf]
Axial patterning of embryos from RNA null mothers with genomic transgenes as indicated.

S4 Fig [pdf]
OSK protein expression at the posterior pole of SRS mutants.

S5 Fig [pdf]
Transport to the oocyte is not disrupted for mRNA with mutations in SRSs 1 and 5.

S1 File [xlsx]
Numerical data for figures.